NCT03737370 2025-10-07
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
Tufts Medical Center
Phase 1 Completed
Clinical Trials
20 trialsNCT03304418 2025-04-30
RROPE
University of Utah
Phase 2 Completed
NCT03076203 2025-04-29
Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)
Thomas Jefferson University
Phase 1 Completed
NCT03093428 2025-03-28
Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03002220 2024-12-11
EXCAAPE
MedSIR
Phase 2 Completed
NCT02903160 2024-02-07
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT02346526 2022-09-29
A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT03223597 2022-04-15
ROTOR
The Netherlands Cancer Institute
Completed
NCT02135484 2022-02-17
Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases
M.D. Anderson Cancer Center
Phase NA Completed
NCT02366130 2021-10-07
Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03062254 2021-09-21
Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2 Completed
NCT04995614 2021-08-09
Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223
Radboud University Medical Center
Completed
NCT02463799 2021-07-08
Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02283749 2021-02-02
BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
Brown University
Phase 2 Completed
NCT02199197 2020-10-30
Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer
University of Utah
Phase 2 Completed
NCT02406521 2020-03-04
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02390934 2019-06-11
RAD-THYR
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT03368989 2019-06-11
The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.
The University of Texas Health Science Center, Houston
Completed
NCT02507570 2019-03-19
Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis
Carolina Research Professionals, LLC
Phase 2 Completed
NCT02097303 2018-02-01
eRADicAte
Carolina Research Professionals, LLC
Phase 2 Completed